Showing 1281-1290 of 21420 results for "".
- Darvadstrocel Misses Primary Endpoint in ADMIRE CD II Trialhttps://reachmd.com/news/darvadstrocel-misses-primary-endpoint-in-admire-cd-ii-trial/2486932/Key Takeaways Week-24 combined remission was similar between darvadstrocel and placebo, and the primary endpoint was not met. Key secondary efficacy measures, including clinical remission at week 24 and time to clinical remission, were also similar bet
- Quintuple GLP-1R-GIPR-PPAR Agonism Improves Mouse Metabolismhttps://reachmd.com/news/glp-1r-gipr-ppar-agonism-mouse-metabolism/2486919/Key Takeaways In mouse models, a novel “quintuple agonist” combiningGLP-1 and GIP receptor activation with triple PPAR (α/γ/δ) agonism outperformed semaglutide and GLP-1/GIP co-agonism in reducing body weight, food intake, and blood glucose. Safety fin
- Luvadaxistat Fails To Improve Cognition in ERUDITE Phase 2 Trialhttps://reachmd.com/news/luvadaxistat-fails-to-improve-cognition-in-erudite-phase-2-trial/2486910/Key Takeaways Neither the 20 mg nor 50 mg dose of luvadaxistat improved the primary cognitive endpoint versus placebo at Day 98. Secondary cognitive, functional, and clinical measures also did not differ significantly from placebo. Adverse eve
- RAAS Inhibition vs Calcium Channe Blockade in Pediatric CKDhttps://reachmd.com/news/raas-inhibition-vs-ccb-in-pediatric-ckd/2486907/Key Takeaways First-line RAAS inhibition was associated with fewer kidney replacement therapy events over 2 years than calcium channel blockade. RAAS inhibition was also associated with a lower secondary kidney composite risk and less time with systoli
- Comparative Evidence for IgA Nephropathy Therapies in a Network Meta-Analysishttps://reachmd.com/news/comparative-evidence-for-iga-nephropathy-therapies-in-a-network-meta-analysis/2486909/Key Takeaways Nefecon was associated with the most favorable eGFR slope point estimate and the highest SUCRA ranking, although uncertainty remained. Methylprednisolone showed the largest UPCR reductions versus placebo, while iptacopan and sibeprenlimab
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://reachmd.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Analysis: PRS Improves Melanoma Risk Predictionhttps://reachmd.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a
- Fecal Microbiota Transplant Did Not Improve MDRO Decolonizationhttps://reachmd.com/news/fecal-microbiota-transplant-mdro-decolonization/2486885/Key Takeaways No significant difference in 4-week MDRO decolonization was observed between FMT and sham. Reductions in AMR genes also did not differ significantly, and adverse events were similar across groups. FMT increased bacterial diversit
- Hepatic Arterial Infusion Oxaliplatin After Colorectal Liver Metastasis Resectionhttps://reachmd.com/news/hepatic-arterial-infusion-oxaliplatin-after-colorectal-liver-metastasis-resection/2486884/Key Takeaways Longer hepatic recurrence-free survival was observed with HAI oxaliplatin plus IV LV5FU2 than with IV oxaliplatin plus IV LV5FU2 after surgery for four or more colorectal liver metastases. Recurrence-free survival also favored HAI, while
- Randomized Trial Tests Platelet Rich Plasma for Grade 2 Hamstring Injurieshttps://reachmd.com/news/randomized-trial-tests-platelet-rich-plasma-for-grade-2-hamstring-injuries/2486851/Key Takeaways This randomized trial compared platelet rich plasma with standard therapy alone in grade 2 hamstring muscle injuries. Reported outcome domains included the recovery course, return to play or return to sport, pain-related measures, radiolo